History of acid suppression: Focus on the hospital setting

Pharmacotherapy

Volumn 23, Issue 10 I, 2003, Pages

  Garnett, William R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CHOLINERGIC RECEPTOR; ESOMEPRAZOLE; FAMOTIDINE; GASTRIN; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; MISOPROSTOL; NIZATIDINE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE;

CONFERENCE PAPER; CONSTIPATION; CRITICAL ILLNESS; DIARRHEA; DUODENUM ULCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HEARTBURN; HELICOBACTER PYLORI; HOSPITAL PATIENT; HUMAN; HYPERMAGNESEMIA; METABOLIC ALKALOSIS; PATIENT COMPLIANCE; PROPHYLAXIS; STOMACH PH; STOMACH PROTECTION; STRESS ULCER; ZOLLINGER ELLISON SYNDROME;

ANTI-ULCER AGENTS; CLINICAL TRIALS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PEPTIC ULCER; PROTON PUMPS;

EID: 0141865624     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.13.56S.31932     Document Type: Conference Paper

References (32)

1. Vakil N, Fennerty B. The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. Am J Med 1996;100:60S-3.
2. Modlin IM, Sachs G, eds. Evolution of the disease. In: Acid related diseases: biology and treatment. Konstanz, Germany: Schnetztor-Verlag GmbH D-Konstanz, 1998:265-71.
3. Erstad BL. Proton-pump inhibitors for acute peptic ulcer bleeding. Ann Pharmacother 2001;35:730-40.
4. ASHP Commission on Therapeutics. ASHP therapeutic guidelines on stress ulcer prophylaxis and approved by the ASHP Board of Directors on November 14, 1998. Am J Health-Syst Pharm 1999;56:347-79.
5. Erstad BL, Barletta JF, Jacobi J, Killian AD, Kramer KM, Martin SJ. Survey of stress ulcer prophylaxis. Crit Care 1999;3:145-9.
6. Erstad BL, Camamo JM, Miller MJ, Webber AM, Fortune J. Impacting cost and appropriateness of stress ulcer prophylaxis at a university medical center. Crit Care Med 1997;25:1678-84.
7. Winkelstein A. Peptic esophagitis: a new clinical entity. JAMA 1935;104:906-9.
8. Peterson WL, Sturdevant RA, Frankl HD, et al. Healing of duodenal ulcer with an antacid regimen. N Engl J Med 1977;297:341-5.
9. Baron JH. Treatments of peptic ulcer. Mt Sinai J Med 2000;67:63-7.
10. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000;118:S9-31.
11. Hayllar J, Macpherson A, Bjarnason I. Gastroprotection and nonsteroidal anti-inflammatory drugs (NSAIDS). Rationale and clinical implications. Drug Saf 1992;7:86-105.
12. Koch M, Dezi A, Tarquini M, Capurso L. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. Dig Liver Dis 2000;32:138-51.
13. Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhea in the elderly. Drugs Aging 1998;13:245-53.
14. Ben Menachem T, Fogel R, Patel RV, et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. Ann Intern Med 1994;121:568-75.
15. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian critical care trials group. N Engl J Med 1998;338:791-7.
16. Modlin IM, Sachs G, eds. The parietal cell. In: Acid related diseases: biology and treatment. Konstanz, Germany: Schnetztor-Verlag GmbH D-Konstanz, 1998:92-109.
17. Ash AS, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol 1966;27:427-39.
18. 2-receptors. Nature 1972;236:385-90.
19. 2-receptor antagonists. In: Gastrointestinal pharmacotherapy. Philadelphia: WB Saunders, 1993:47-84.
20. 2 receptor antagonist. Gut 1989;30:449-54.
21. Modlin IM, Sachs G, eds. Inhibition of the histamine 2 receptor. In: Acid related diseases: biology and treatment. Konstanz, Germany: Schnetztor-Verlag GmbH D-Konstanz, 1998:121-5.
22. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994;106:60-4.
23. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):59-67.
24. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990;99:345-51.
25. Ours TM, Fackler WK, Richter J, Vaezi MF. Esophageal pH reflux symptom response to various treatment regimens: clinical relevance of nocturnal acid breakthrough [abstr]. Am J Gastroenterol 2001;96:22.
26. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs 1997;54:581-96.
27. Shuman RB, Schuster DP, Zuckerman GR. Prophylactic therapy for stress ulcer bleeding: a reappraisal. Ann Intern Med 1987;106:562-7.
28. Modlin IM, Sachs G, eds. Inhibition of the gastric acid pump. In: Acid related diseases: biology and treatment. Konstanz, Germany: Schnetztor-Verlag GmbH D-Konstanz, 1998:126-45.
29. AstraZeneca Pharmaceuticals. Nexium (esomeprazole) package insert. Wilmington, DE; 2000.
30. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. The continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995;9:363-78.
31. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000;40:52-62.
32. Brunner G, Luna P, Hartmann M, Wurst W. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. Yale J Biol Med 1996;69:225-31.